Advertisement
U.S. Markets close in 2 hrs 9 mins

Vanda Pharmaceuticals Inc. (VNDA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Visitors trend2W10W9M
5.05+0.16 (+3.17%)
As of 01:50PM EST. Market open.
Advertisement
Show:
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
182,022
192,640
254,382
268,682
248,168
Cost of Revenue
12,696
14,796
24,282
25,629
23,364
Gross Profit
169,326
177,844
230,100
243,053
224,804
Operating Expense
201,796
191,796
223,771
200,888
197,565
Operating Income
-32,470
-13,952
6,329
42,165
27,239
Other Income Expense
20,509
20,291
4,971
199
4,416
Pretax Income
-11,961
6,339
11,300
42,364
31,655
Tax Provision
-1,034
3,830
5,025
9,212
8,318
Net Income Common Stockholders
-10,927
2,509
6,275
33,152
23,337
Diluted NI Available to Com Stockholders
-10,927
2,509
6,275
33,152
23,337
Basic EPS
0.11
0.04
0.11
0.60
0.43
Diluted EPS
0.11
0.04
0.11
0.58
0.42
Basic Average Shares
56,462
57,381
56,462
55,548
54,428
Diluted Average Shares
56,983
57,558
56,983
56,922
55,191
Total Operating Income as Reported
-32,470
-13,952
6,329
42,165
27,239
Total Expenses
214,492
206,592
248,053
226,517
220,929
Net Income from Continuing & Discontinued Operation
-10,927
2,509
6,275
33,152
23,337
Normalized Income
-10,927
2,509
6,275
33,152
23,337
EBIT
-32,470
-13,952
6,329
42,165
27,239
EBITDA
-26,540
-10,942
9,062
45,006
30,103
Reconciled Cost of Revenue
11,869
13,876
23,065
24,266
21,978
Reconciled Depreciation
5,930
3,010
2,733
2,841
2,864
Net Income from Continuing Operation Net Minority Interest
-10,927
2,509
6,275
33,152
23,337
Normalized EBITDA
-26,540
-10,942
9,062
45,006
30,103
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0